Cargando…

The risk of liver cancer in autoimmune liver diseases

Hepatocellular carcinoma (HCC), the dominant primary malignancy of the liver, has almost invariably a fatal outcome that can be averted only by early diagnosis and treatment. While the close association of HCC with chronic viral hepatitis and alcohol abuse has impacted favourably on screening and tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lleo, Ana, de Boer, Ynto S., Liberal, Rodrigo, Colombo, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Early Diagnosis and Therapeutic Advances for Liver Cancer: From Bench to Bedside
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628541/ https://www.ncbi.nlm.nih.gov/pubmed/31320937 http://dx.doi.org/10.1177/1758835919861914

Ejemplares similares

Single nucleotide polymorphisms in telomere length-related genes are associated with hepatocellular carcinoma risk in the Chinese Han population
por: Huang, Peng, et al.
Publicado: (2020)

Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
por: Xu, Weiqi, et al.
Publicado: (2019)

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019)

Management of patients with intermediate stage hepatocellular carcinoma
por: Prince, David, et al.
Publicado: (2020)

Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization
por: Lee, Hsin-Lun, et al.
Publicado: (2019)

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
por: Liu, Xuan, et al.
Publicado: (2020)

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
por: Ono, Atsushi, et al.
Publicado: (2020)

Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis
por: Méndez-Blanco, Carolina, et al.
Publicado: (2021)

Endovascular interventions for central vein stenosis
por: Agarwal, Anil K.
Publicado: (2015)

Current progress in ABO-incompatible kidney transplantation
por: Koo, Tai Yeon, et al.
Publicado: (2015)

RNA sequencing of the nephron transcriptome: a technical note
por: Lee, Jae Wook
Publicado: (2015)

Organ-on-a-chip and the kidney
por: Kim, Sejoong, et al.
Publicado: (2015)

Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers
por: Ayoub, Walid S., et al.
Publicado: (2019)

Neuro-tracing approach to study kidney innervation: a technical note
por: Lee, Sanghee, et al.
Publicado: (2017)

Messenger RNA vaccines against SARS-CoV-2
por: Topol, Eric J.
Publicado: (2021)

Genetic Stratification in Myeloid Diseases: From Risk Assessment to Clinical Decision Support Tool
por: Ofran, Yishai
Publicado: (2014)

Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting
por: Ringelstein-Harlev, Shimrit, et al.
Publicado: (2014)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease
por: Lin, Chuan-Hao, et al.
Publicado: (2018)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer
por: Tsoli, Maria, et al.
Publicado: (2018)

How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy
por: Zhang, Bin, et al.
Publicado: (2016)

Impact of Heparanase and the Tumor Microenvironment on Cancer Metastasis and Angiogenesis: Basic Aspects and Clinical Applications
por: Vlodavsky, Israel, et al.
Publicado: (2011)

Dendritic Cell Cancer Vaccines: From the Bench to the Bedside
por: Katz, Tamar, et al.
Publicado: (2014)

ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies
por: Sarig, Galit
Publicado: (2014)

Stem Cells for Diabetes Complications: A Future Potential Cure
por: Khamaisi, Mogher, et al.
Publicado: (2017)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
por: Graziano, Vincenzo, et al.
Publicado: (2015)

Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
por: Lipkin, Jacob S, et al.
Publicado: (2015)

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
por: Wyluda, Edward J, et al.
Publicado: (2015)

Metformin: a modulator of bevacizumab activity in cancer? A case report
por: Indraccolo, Stefano, et al.
Publicado: (2015)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach
por: Caggiari, Laura, et al.
Publicado: (2017)

Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing
por: Yang, Shanshan, et al.
Publicado: (2017)

HIF2A germline–mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma
por: Liu, Qiuli, et al.
Publicado: (2017)

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy
por: Liu, Qiuli, et al.
Publicado: (2018)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
por: Zhu, You-cai, et al.
Publicado: (2018)

Successful treatment using apatinib in intractable brain edema: A case report and literatures review
por: Song, Yanqiu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hgs4kp28slbl7us3t1bko7j3su